Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending December 20, 2020 Antiandrogens linked to higher risk for fall, fracture in men with prostate cancer, Prostate cancer: Active surveillance not linked to higher mortality in Black men, Prostate cancer: Active surveillance is safe in the long term, Metastatic prostate cancer: EBRT improves survival in elderly patients with low PSA, Prostate cancer: Prolonged ADT reduces cardiorespiratory fitness, raises CV morality risk, More must reads Must reads for theWeek ending November 29, 2020 Long-term treatment-related quality of life outcomes in men with localized prostate cancer, Depression may not be causally linked to prostate cancer risk, Impact of PLND on oncologic outcomes after radical prostatectomy in men with prostate cancer, Adjuvant vs salvage radiotherapy for early prostate cancer after surgery, Prostate cancer: Adjuvant radiotherapy fails in phase 3 trial, More must readsMust reads for theWeek ending November 15, 2020 mCRPC: First-line abiraterone + ipatasertib shows promise, mCRPC: Cabazitaxel tops enzalutamide and abiraterone in quality of life outcomes, Prostate cancer: Does ADT increase risk of cardiovascular and cerebrovascular diseases?, High intake of soy and isoflavones may raise prostate cancer mortality risk, Elevated posttreatment free PSA ratio tied to worse outcomes in prostate cancer, More must readsMust reads for theWeek ending October 18, 2020 Nivolumab plus ipilimumab shows activity in mCRPC, CRPC: Comparison of apalutamide, enzalutamide, and darolutamide, ADT beneficial for prostate cancer patients with unfavorable intermediate risk, CRPC: Add-on darolutamide improves overall survival, Olaparib prolongs overall survival in metastatic castration-resistant prostate cancer, More must readsMust reads for theWeek ending October 4, 2020 Favorable-risk prostate cancer: Deferred and upfront surgery have similar outcomes, Delayed radical prostatectomy not linked to adverse oncological outcomes, Antiandrogen monotherapy may raise dementia risk in patients with prostate cancer, CRPC: Postdocetaxel ipilimumab improves overall survival in the long term, Apalutamide plus ADT improves overall survival in castration-resistant prostate cancer, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 last »
